Finerenone Delivers Heart Benefits Independent of Pressure
Finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, provides cardiovascular benefits for patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) that are independent of its blood pressure-lowering effects. A post hoc analysis of the FINEARTS-HF trial, published in JAMA Cardiology, confirms the medication is associated with early and sustained reductions in systolic blood pressure while maintaining a consistent safety profile across various baseline blood pressure levels.
Trial Data on Cardiovascular Risk Reduction
The FINEARTS-HF trial was a double-blind, randomized study involving 6,001 patients with symptomatic heart failure and an ejection fraction of at least 40%. Participants received either once-daily finerenone or a placebo alongside standard care. Over a median follow-up of 32 months, researchers found that finerenone reduced the risk of cardiovascular death and worsening heart failure by 16%.
Dissecting the Blood Pressure Mechanism
Researchers observed sustained reductions in systolic levels beginning as early as one month into treatment, with a mean difference of 2.8 mm Hg between the treatment and placebo groups. Crucially, the study authors noted that the blood pressure-lowering effect did not significantly mediate the primary cardiovascular benefits observed in the trial. This suggests that while finerenone helps manage blood pressure, its protective effects on the heart operate through additional physiological pathways.
Safety Profile Across Baseline Readings
To determine if baseline blood pressure influenced treatment efficacy or safety, researchers categorized participants into four groups: less than 120 mm Hg, 120–129 mm Hg, 130–139 mm Hg, and 140 mm Hg or higher. The analysis demonstrated that the treatment remained safe regardless of the patient’s starting blood pressure. Serious adverse events and instances leading to treatment discontinuation occurred at similar rates in both the finerenone and placebo groups.
Clinical Consistency in Hypertensive Patients
John W. Ostrominski, MD, MPH, a fellow in cardiovascular medicine at Brigham and Women’s Hospital and Harvard Medical School, and his colleagues, emphasized that while hypertension affects approximately 90% of patients with HFmrEF or HFpEF, the benefits of finerenone appear consistent across a broad spectrum of blood pressure readings.
FDA Approval and Limitations
Based on the data from the FINEARTS-HF trial, the FDA approved finerenone in 2025 for the treatment of heart failure with mildly reduced or preserved ejection fraction. Study authors noted that higher doses—up to 40 mg for eligible patients—correlated with greater reductions in systolic blood pressure. Despite these findings, researchers acknowledged that the trial did not utilize 24-hour ambulatory blood pressure monitoring. Furthermore, exclusion criteria regarding kidney function and uncontrolled blood pressure may limit how broadly these results apply to the general heart failure population. Nevertheless, the study supports the integration of finerenone into standard care protocols for patients with heart failure who maintain an ejection fraction of 40% or higher.